Healthcare provider profile · identity verified

Brian Hurd Carroll, MD

Family Practice · CHARLOTTE, NC · NPI 1184684151

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	333	97
Amlodipine Besylate	Amlodipine Besylate	257	84
Rosuvastatin Calcium	Rosuvastatin Calcium	212	66
Omeprazole	Omeprazole	188	54
Levothyroxine Sodium	Levothyroxine Sodium	180	48
Losartan Potassium	Losartan Potassium	164	56
Pantoprazole Sodium	Pantoprazole Sodium	149	50
Montelukast Sodium	Montelukast Sodium	119	40
Trazodone Hcl	Trazodone Hcl	109	28
Lisinopril	Lisinopril	108	31
Tramadol Hcl	Tramadol Hcl	107	26
Ezetimibe	Ezetimibe	101	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	100	26
Metoprolol Succinate	Metoprolol Succinate	98	31
Gabapentin	Gabapentin	90	31
Albuterol Sulfate Hfa	Albuterol Sulfate	87	29
Prednisone	Prednisone	87	65
Tamsulosin Hcl	Tamsulosin Hcl	87	27
Metformin Hcl	Metformin Hcl	80	22
Fluoxetine Hcl	Fluoxetine Hcl	79	22
Allopurinol	Allopurinol	75	17
Eliquis	Apixaban	74	22
Lovastatin	Lovastatin	73	25
Hydrochlorothiazide	Hydrochlorothiazide	71	24
Carvedilol	Carvedilol	62	20
Sertraline Hcl	Sertraline Hcl	59	14
Furosemide	Furosemide	50	17
Diclofenac Sodium	Diclofenac Sodium	48	15
Alprazolam	Alprazolam	47	11
Metoprolol Tartrate	Metoprolol Tartrate	47	14
Metformin Hcl Er	Metformin Hcl	45	17
Bupropion Xl	Bupropion Hcl	44	suppressed
Ondansetron Hcl	Ondansetron Hcl	43	17
Chlorthalidone	Chlorthalidone	42	16
Duloxetine Hcl	Duloxetine Hcl	41	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	41	20
Azithromycin	Azithromycin	40	34
Tizanidine Hcl	Tizanidine Hcl	39	13
Zolpidem Tartrate	Zolpidem Tartrate	39	14
Citalopram Hbr	Citalopram Hydrobromide	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	36	suppressed
Fluticasone Propionate	Fluticasone Propionate	34	17
Atenolol	Atenolol	33	suppressed
Finasteride	Finasteride	33	12
Meloxicam	Meloxicam	32	suppressed
Potassium Chloride	Potassium Chloride	31	11
Clopidogrel	Clopidogrel Bisulfate	30	suppressed
Ozempic	Semaglutide	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	suppressed
Myrbetriq	Mirabegron	29	suppressed
Valsartan	Valsartan	29	suppressed
Celecoxib	Celecoxib	28	11
Alendronate Sodium	Alendronate Sodium	27	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	27	suppressed
Sucralfate	Sucralfate	26	11
Clonidine Hcl	Clonidine Hcl	25	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	25	12
Jardiance	Empagliflozin	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	23	suppressed
Symbicort	Budesonide/Formoterol Fumarate	23	suppressed
Buspirone Hcl	Buspirone Hcl	22	suppressed
Fenofibrate	Fenofibrate	22	suppressed
Cephalexin	Cephalexin	20	19
Valacyclovir	Valacyclovir Hcl	20	suppressed
Ventolin Hfa	Albuterol Sulfate	20	suppressed
Xarelto	Rivaroxaban	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Methocarbamol	Methocarbamol	19	11
Lorazepam	Lorazepam	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Famotidine	Famotidine	17	suppressed
Januvia	Sitagliptin Phosphate	17	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	17	suppressed
Simvastatin	Simvastatin	17	suppressed
Spironolactone	Spironolactone	17	suppressed
Donepezil Hcl	Donepezil Hcl	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	12
Ibuprofen	Ibuprofen	16	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	16	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Glipizide	Glipizide	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	14	suppressed
Levofloxacin	Levofloxacin	14	suppressed
Clindamycin Hcl	Clindamycin Hcl	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Sildenafil Citrate	Sildenafil Citrate	13	suppressed
Torsemide	Torsemide	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	12	suppressed
Creon	Lipase/Protease/Amylase	12	suppressed
Divalproex Sodium	Divalproex Sodium	12	suppressed
Fluphenazine Hcl	Fluphenazine Hcl	12	suppressed
Levalbuterol Tartrate Hfa	Levalbuterol Tartrate	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Pentoxifylline	Pentoxifylline	12	suppressed
Spiriva Handihaler	Tiotropium Bromide	12	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	12	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	11	suppressed
Baclofen	Baclofen	11	suppressed
Klor-Con M20	Potassium Chloride	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Naproxen	Naproxen	11	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error